Technology | June 08, 2009

Angiotech Gets FDA Clearance for Option Inferior Vena Cava Filter

The Option Inferior Vena Cava Filter. Reprinted with permission of Angiotech Pharmaceuticals.

June 8, 2009 - Angiotech Pharmaceuticals Inc. today said the FDA granted 510(k) clearance for the Option Inferior Vena Cava (IVC) Filter for use in both permanent and retrievable indications.

Angiotech holds exclusive worldwide rights to market and distribute the Option IVC Filter, which it obtained in a license agreement with privately held Rex Medical LP.

The Option IVC Filter is used for the prevention of recurrent pulmonary embolism (PE). The device is implanted, typically by interventional radiologists in a minimally invasive procedure, into the body's inferior vena cava to prevent PE. Option is specifically designed for use as both a permanent or temporary implant.

Filter’s clinical study data shows a 92 percent retrieval success, and a retrieval at up to 175 days post-implantation.

According to market analysis conducted by Millennium Research Group, the U.S. market for IVC filters was approximately $200 million in 2007 (with approximately 160,000 IVC filters implanted). This market is predicted to grow to $300 million by 2012. IVC filters can be permanent or retrievable (where a physician can remove them when the patients no longer require them). Retrievable filters accounted for approximately two-thirds of the market in 2007. The Option IVC Filter is designed to be used in both permanent and retrievable indications and has been successfully retrieved at long intervals - up to 175 days post-implantation in the U.S. clinical trial.

The results of a recently concluded clinical trial for the Option IVC Filter were presented by the study's Principle Investigator Matthew Johnson, M.D., at the 34th Annual Scientific Meeting of the Society of Interventional Radiology in March of 2009. The single-arm, multicenter clinical trial, which enrolled 100 patients with a mean age of 59 years, was designed to evaluate the safety and efficacy of the Option IVC filter when used both as a permanent and temporary filter in patients at increased risk for pulmonary embolism. In the trial, clinical success, defined as placement technical success without subsequent PE, significant filter migration or embolization, symptomatic thrombosis or other complications requiring filter removal or intervention, was achieved in 88 percent of subjects. Retrieval success was achieved in 92 percent (36/39) of cases where retrieval was attempted, with a mean implantation time in those cases of 67 days. The safety profile of the Option IVC Filter was consistent with other currently marketed IVC filters.

For more

Related Content

First BTG Sentry Bioconvertible IVC Filter Implanted in U.S.
News | Vena Cava Filters | December 04, 2018
BTG plc announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry...
Florida Law Firm Sues Cordis, Blames Death on IVC Filter
News | Vena Cava Filters | January 02, 2018
January 2, 2018 — Osborne & Associates Law Firm, P.A., of Boca Raton, Fla., has filed suit in Palm Beach Circuit
News | Vena Cava Filters | September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Videos | Vena Cava Filters | July 24, 2012
This video, provided by Crux Biomedical, demonstrates the implantation of the FDA-cleared Crux VCF inferior vena cava
Videos | Vena Cava Filters | April 06, 2012
The Crux inferior vena cava (IVC) filter was designed for easy deployment and later retrival.
Videos | Vena Cava Filters | April 06, 2012
The Crux inferior vena cava (IVC) filter was designed for easy deployment and later retrieval.
Overlay Init